Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 8:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 2,339 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Pharmacokinetics and Pharmacodynamics Clear all

Conditions: Psoriasis
Interventions: AMG 557 or PLACEBO; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 6
States / cities: Birmingham, Alabama • Reno, Nevada • Portland, Oregon + 2 more

Conditions: Healthy
Interventions: VBY-891, Placebo; Drug
Lead sponsor: Virobay Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 89 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Healthy Volunteers
Interventions: CC-11050; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Alzheimer's Disease
Interventions: Velusetrag, Placebo; Drug
Lead sponsor: Alfasigma S.p.A.; Industry
Eligibility: 65 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Miramar, Florida

Conditions: Anemia
Interventions: ACE-536, Placebo; Biological · Other
Lead sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA; Industry
Eligibility: 45 Years to 75 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Plaque Psoriasis
Interventions: Calcitriol 3 mcg/g ointment; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 2 Years to 12 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 8
States / cities: San Diego, California • Indianapolis, Indiana • Ann Arbor, Michigan + 5 more

Conditions: Kidney Failure, Chronic
Interventions: LY3113593, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 3
States / cities: Glendale, California • Orlando, Florida • Minneapolis, Minnesota

Conditions: Osteogenesis Imperfecta
Interventions: BPS804; Drug
Lead sponsor: Ultragenyx Pharmaceutical Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Anaheim, California • Miramar, Florida

Conditions: Pompe Disease
Interventions: Duvoglustat; Drug
Lead sponsor: Amicus Therapeutics; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: Sepsis
Interventions: Doripenem; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Cancer
Interventions: BMS-906024; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 6
States / cities: Los Angeles, California • Atlanta, Georgia • Detroit, Michigan + 3 more

Conditions: Vulvo Vaginal Atrophy (VVA)
Interventions: Lasofoxifene Tartrate; Drug
Lead sponsor: Azure Biotech Inc.; Industry
Eligibility: 45 Years to 60 Years · Female only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: GSK3862995B, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Cypress, California • Las Vegas, Nevada

Conditions: Contraception, Pharmacogenomic Drug Interaction
Interventions: Desogestrel / Ethinyl Estradiol Pill; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 700 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: Aurora, Colorado • New Haven, Connecticut

Conditions: Relapsed/Refractory Peripheral T-cell Lymphoma
Interventions: Tolinapant, Decitabine + Cedazuridine; Drug
Lead sponsor: Taiho Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 6
States / cities: Aurora, Colorado • Tampa, Florida • Atlanta, Georgia + 3 more

Conditions: HIV Prevention
Interventions: DuoGel; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cancer
Interventions: Dabrafenib, Trametinib, Panitumumab, 5-fluorouracil; Drug · Device
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 8
States / cities: Scottsdale, Arizona • San Francisco, California • Boston, Massachusetts + 4 more

Conditions: Heparin-induced Thrombocytopenia
Interventions: VLX-1005, Argatroban; Drug
Lead sponsor: Veralox Therapeutics; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Multifocal Motor Neuropathy (MMN)
Interventions: ARGX-117, Placebo; Biological · Other
Lead sponsor: argenx; Industry
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 6
States / cities: Scottsdale, Arizona • Glenview, Illinois • Minneapolis, Minnesota + 3 more

Conditions: Healthy Volunteers
Interventions: CHK336, Placebo; Drug
Lead sponsor: Chinook Therapeutics, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Heart Failure, Healthy Volunteer
Interventions: AMG 986 IV, AMG 986 PO, Placebo PO, Placebo IV; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 182 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 8
States / cities: Anaheim, California • Tustin, California • Jacksonville, Florida + 5 more

Conditions: Multiple Sclerosis
Interventions: Teriflunomide, Placebo (for teriflunomide), Glatiramer Acetate (GA); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Diabetes Mellitus, Type 1
Interventions: Placebo, PF-06342674 Dose A, PF-06342674 Dose B, PF-06342674 Dose C, PF-06342674 Dose D; Drug · Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 21
States / cities: San Diego, California • San Francisco, California • Aurora, Colorado + 7 more

Conditions: Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer, NSCLC
Interventions: PRTH-101, Pembrolizumab; Biological
Lead sponsor: Incendia Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 11
States / cities: Scottsdale, Arizona • New Haven, Connecticut • Boston, Massachusetts + 7 more

Search by objective public record fields.

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 557 in Adults With Psoriasis

Safety Study of VBY-891 in Healthy Volunteers After Single or Multiple (7 Days) of Oral Dosing (VBY891P1)

A Study to Evaluate the Safety, Tolerability Pharmacokinetics, and Pharmacodynamics of a New Spray Dried Dispersion (SDD) Formulation of CC-11050 After Single Dose of CC-11050 and to Evaluate the Pharmacokinetics of CC-11050 Under Fasted and Fed Conditions and After Coadministration With Omeprazole

Safety, Pharmacokinetics and Pharmacodynamics of Velusetrag in Healthy Elderly Subjects

Study of ACE-536 in Healthy Postmenopausal Women

PK and PD Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis

A Study of LY3113593 in Healthy Participants and Participants With Chronic Kidney Disease Treated With Hemodialysis

Safety, Pharmacokinetics and Pharmacodynamics of BPS804 in Osteogenesis Imperfecta

Study to Evaluate the Safety of AT2220 (Duvoglustat) in Pompe Disease

Pharmacokinetic and Pharmacodynamic Evaluation of Doripenem in Critically Ill Trauma Patients

Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors

Proof of Concept Study of Vaginal AZU-101 in Vulvovaginal Atrophy in Postmenopausal Women

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GSK3862995B Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and European Ancestry

Oral Contraceptive Pill (OCP) Pharmacogenomics

A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)

ImQuest (IQP) DuoGel Phase 1 Pharmacokinetic Study

BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)

A Phase I Study of the Co-administration of VLX-1005 and Argatroban in Healthy Human Subjects

A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CHK-336 in Healthy Volunteers

Study to Evaluate the Safety and Tolerability of AMG 986 in Healthy Volunteers and Heart Failure Patients

Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis

A Study To Assess The Safety Of PF-06342674 In Adults With Type 1 Diabetes

A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies